Prophylaxis and Treatment of COVID-19

Exclusion Criteria

• •1. Population A: Adults seeking care or testing for SARS-CoV-2 or ILI
• •a. Laboratory confirmed SARS-CoV-2 infection 6 to 90 days prior to enrollment
• •2. Population B: Adult contacts of SARS-CoV-2 or ILI infected individuals
• •1. Symptoms attributed to COVID-19 or ILI as assessed by a medical provider
• •2. Positive molecular or antigen test for SARS-CoV-2 from any upper respiratory specimen within 90 days prior to enrollment
• •3. SARS-CoV-2 vaccination within 90 days prior to enrollment EXCEPT if severely immunocompromised or a known vaccine non-responder
• •* Severely immunocompromised or a known vaccine non-responder defined as: solid organ or stem cell recipient, B cell leukemia, receiving B cell depletion therapy (e.g., rituximab), agammaglobulinemia, or negative serology ≥ 2 weeks after vaccination with two doses of a vaccine
• •4. Positive PCR test for acute respiratory infection including but not limited to influenza, RSV, adenovirus, parainfluenza virus, rhinovirus, metapneumovirus, Bordatella Pertussis, Chlamydia Pneumonia, coronavirus (other than SARS-CoV-2), mycoplasma within 7 days of enrollment
• •5. Hospital admission at the time of enrollment
• •* Hospitalization will be defined as requiring medical care not available in an outpatient setting for greater than 24 hours.
• •* Hospitalization for isolation or quarantine requirements or for social reasons will NOT constitute an exclusion criterion
• •For Both populations:
• •1. Absence of informed consent
• •2. Individuals who the study investigators believe are unable to comply with the requirements of the study